Sifting through countless of stocks in the Health Care Equipment & Supplies industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in CONMED Corporation, RxSight or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how CONMED Corporation, RxSight and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About CONMED Corporation, RxSight and Inc.

CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as supporting products include powered resection instruments , fluid management, and visualization systems and the related single-use products that enable surgeons to perform minimally invasive sports medicine surgeries. It also provides battery-powered, autoclavable, large, and small bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under the Hall surgical brand name. In addition, the company offers general surgery products, such as clinical insufflation systems under the AirSeal brand; smoke removal devices under the Buffalo Filter brand; endomechanical products, including the Anchor1 line of tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors, used in minimally invasive surgeries; and electrosurgical solution comprise monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems, and other accessories. Further, it provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products to treat diseases of dilation, hemostasis, biliary, stricture management, infection prevention, and patient monitoring include ECG electrodes, EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. The company was incorporated in 1970 and is headquartered in Largo, Florida.

RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company’s RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is headquartered in Aliso Viejo, California.

Latest Health Care Equipment & Supplies and CONMED Corporation, RxSight, Inc. Stock News

As of July 31, 2026, CONMED Corporation had a $1.4 billion market capitalization, compared to the Health Care Equipment & Supplies median of $337.2 million. CONMED Corporation’s stock is up 14% in 2026, up 8.5% in the previous five trading days and down 7.66% in the past year.

Currently, CONMED Corporation’s price-earnings ratio is 25.1. CONMED Corporation’s trailing 12-month revenue is $1.4 billion with a 4.1% net profit margin. Year-over-year quarterly sales growth most recently was 0.4%. Analysts expect adjusted earnings to reach $4.536 per share for the current fiscal year. CONMED Corporation does not currently pay a dividend.

As of July 31, 2026, RxSight, Inc. had a $249.4 million market cap, putting it in the 30th percentile of all stocks. RxSight, Inc.’s stock is down 42.3% in 2026, up 15.8% in the previous five trading days and down 24.5% in the past year.

Currently, RxSight, Inc. does not have a price-earnings ratio. RxSight, Inc.’s trailing 12-month revenue is $127.5 million with a -36.6% net profit margin. Year-over-year quarterly sales growth most recently was -18.5%. Analysts expect adjusted earnings to reach $-0.668 per share for the current fiscal year. RxSight, Inc. does not currently pay a dividend.

How We Compare CONMED Corporation, RxSight and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at CONMED Corporation, RxSight and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

CONMED Corporation, RxSight and Inc.’s Quality Grades

Company	Ticker	Quality
CONMED Corporation	CNMD	A
RxSight, Inc.	RXST	C

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

CONMED Corporation has a Quality Score of 90, which is Very Strong. RxSight, Inc. has a Quality Score of 56, which is Average.

The Quality Grade Winner: CONMED Corporation

As you can clearly see from the Quality Grade breakdown above, CONMED Corporation has a better overall quality grade than RxSight, Inc.. For investors who are looking for companies with higher quality than others in the same industry, CONMED Corporation could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

CONMED Corporation, RxSight and Inc.’s Momentum Grades

Company	Ticker	Momentum
CONMED Corporation	CNMD	C
RxSight, Inc.	RXST	D

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

CONMED Corporation has a Momentum Score of 53, which is Average. RxSight, Inc. has a Momentum Score of 21, which is Weak.

The Momentum Stock Winner: No Clear Winner

Neither CONMED Corporation, RxSight or Inc. has a strong enough Momentum Grade to be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if CONMED Corporation, RxSight or Inc. is the better investment when it comes to momentum.

CONMED Corporation, RxSight and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
CONMED Corporation	CNMD	A
RxSight, Inc.	RXST	C

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

CONMED Corporation has a Earnings Estimate Score of 86, which is Very Positive. RxSight, Inc. has a Earnings Estimate Score of 48, which is Neutral.

The Earnings Estimate Revisions Grade Winner: CONMED Corporation

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, CONMED Corporation has a better Earnings Estimate Revisions Grade than RxSight, Inc.. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, CONMED Corporation could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other CONMED Corporation, RxSight and Inc. Grades

In addition to Estimate Revisions, Quality and Momentum, A+ Investor also provides grades for Value and Growth.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether CONMED Corporation, RxSight and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, CONMED Corporation, RxSight or Inc. Stock?

Overall, CONMED Corporation stock has a Momentum Score of 53, Estimate Revisions Score of 86 and Quality Score of 90.

RxSight, Inc. stock has a Momentum Score of 21, Estimate Revisions Score of 48 and Quality Score of 56.

Comparing CONMED Corporation, RxSight and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.